Search Results - Daniel A Scott

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence by Erica Chilson, Daniel A. Scott, Beate Schmoele-Thoma, Wendy Watson, Mary M. Moran, Raul Isturiz

    Published in Human Vaccines & Immunotherapeutics (2020-11-01)
    Get full text
    Article


  2. 2

    Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age by Raul E. Isturiz, Cassandra Hall-Murray, John M. McLaughlin, Vincenza Snow, Beate Schmoele-Thoma, Chris Webber, Allison Thompson, Daniel A Scott

    Published in Expert Review of Vaccines (2018-01-01)
    Get full text
    Article


  3. 3

    A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States by David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson

    Published in Human Vaccines & Immunotherapeutics (2021-07-01)
    Get full text
    Article


  4. 4

    A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age by Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson

    Published in Human Vaccines & Immunotherapeutics (2021-08-01)
    Get full text
    Article


  5. 5

    Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease by Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson

    Published in Human Vaccines & Immunotherapeutics (2022-11-01)
    Get full text
    Article


  6. 6

    A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age by Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson

    Published in Human Vaccines & Immunotherapeutics (2023-08-01)
    Get full text
    Article


  7. 7

    Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial by Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma

    Published in Human Vaccines & Immunotherapeutics (2017-09-01)
    Get full text
    Article


  8. 8

    Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a r... by Allison R. Thompson, Nicola P. Klein, H. Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma

    Published in Human Vaccines & Immunotherapeutics (2019-02-01)
    Get full text
    Article


  9. 9

    Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial by Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson

    Published in Human Vaccines & Immunotherapeutics (2023-08-01)
    Get full text
    Article


Search Tools: